TENX

Tenax Therapeutics, Inc.
CAPPED RATING

Tenax Therapeutics, Inc. (TENX) is rated D+ (1.7/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (C+); its weakest is Revisions (F).

Quantitative Factor Evaluation • Updated

Overall Rating
1.7 / 5.0
D+
Value
C+
Factor Score 2.5 / 5.0
Growth
C-
Factor Score 1.9 / 5.0
Profitability
C
Factor Score 2.2 / 5.0
Momentum
D+
Factor Score 1.7 / 5.0
Revisions
F
Factor Score 0.0 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -1.2
EV / EBITDA N/A
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -5.3%
Price Return 12M -76.8%
Catalyst Signal 0.00
Market Cap $73.8M
TTM Revenue N/A
Price / Sales N/A
ROE -64.2%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-15 C+ (2.5) C- (1.9) C (2.2) D+ (1.7) F (0.0) D+ (1.7)
2026-11-08 C+ (2.5) D+ (1.5) C (2.2) C- (2.0) F (0.0) D+ (1.6)
2026-11-01 C+ (2.5) D+ (1.7) C (2.3) F (0.4) F (0.0) D (1.4)
2026-10-25 C+ (2.5) D+ (1.7) C (2.2) F (0.4) F (0.0) D (1.4)
2026-10-18 C+ (2.5) D+ (1.7) C (2.2) F (0.4) F (0.0) D (1.4)
Page 1 of 4